TY - JOUR
T1 - Next generation sequencing in non-small cell lung cancer
T2 - New avenues toward the personalized medicine
AU - Coco, Simona
AU - Truini, Anna
AU - Vanni, Irene
AU - Dal Bello, Maria Giovanna
AU - Alama, Angela
AU - Rijavec, Erika
AU - Genova, Carlo
AU - Barletta, Giulia
AU - Sini, Claudio
AU - Burrafato, Giovanni
AU - Biello, Federica
AU - Boccardo, Francesco
AU - Grossi, Francesco
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Non-small cell lung cancer (NSCLC) is one of the most common causes of cancer-related death worldwide. Based on the patient’s stage of disease, treatment options include surgery, radiotherapy, and chemotherapy. Although chemotherapy remains the main therapeutic approach for advanced NSCLC, targeted therapy represents a good chance of treatment for this subgroup of patients. Currently this approach is based on previous evaluation of clinically relevant mutations and the Sanger sequencing is the main approach to assign mutational status and to guide the appropriate treatment; however this tool is characterized by a low sensitivity. Recently, the advent of next-generation sequencing (NGS) has dramatically revolutionized the molecular knowledge of cancer by increasing the feasibility and possibility to sequence DNA ranging from large scale studies to targeted regions. This review reports an overview of different applications of the NGS as novel approach to study NSCLC, thereby providing information about mutational spectrum of this cancer in order to identify novel targetable mutations and to predict the emergence of drug resistance. All studies demonstrated several advantages of this approach over the traditional tools. In particular the NGS was also able to reveal mutations in low percentage, and to screen the mutational status of different critical samples such as biopsies, cytological samples and circulating plasma DNA, offering innovative diagnostic opportunities. Despite several problems have to be overcome toward the personalized therapy, the NGS represents a highly attractive system to identify mutations improving the outcome of patients with this deadly disease.
AB - Non-small cell lung cancer (NSCLC) is one of the most common causes of cancer-related death worldwide. Based on the patient’s stage of disease, treatment options include surgery, radiotherapy, and chemotherapy. Although chemotherapy remains the main therapeutic approach for advanced NSCLC, targeted therapy represents a good chance of treatment for this subgroup of patients. Currently this approach is based on previous evaluation of clinically relevant mutations and the Sanger sequencing is the main approach to assign mutational status and to guide the appropriate treatment; however this tool is characterized by a low sensitivity. Recently, the advent of next-generation sequencing (NGS) has dramatically revolutionized the molecular knowledge of cancer by increasing the feasibility and possibility to sequence DNA ranging from large scale studies to targeted regions. This review reports an overview of different applications of the NGS as novel approach to study NSCLC, thereby providing information about mutational spectrum of this cancer in order to identify novel targetable mutations and to predict the emergence of drug resistance. All studies demonstrated several advantages of this approach over the traditional tools. In particular the NGS was also able to reveal mutations in low percentage, and to screen the mutational status of different critical samples such as biopsies, cytological samples and circulating plasma DNA, offering innovative diagnostic opportunities. Despite several problems have to be overcome toward the personalized therapy, the NGS represents a highly attractive system to identify mutations improving the outcome of patients with this deadly disease.
KW - Drug resistance
KW - Mutational landscape
KW - Next generation sequencing
KW - NSCLC
KW - Personalized therapy
KW - Targeted sequencing
UR - http://www.scopus.com/inward/record.url?scp=84922311353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922311353&partnerID=8YFLogxK
M3 - Article
C2 - 25495923
AN - SCOPUS:84922311353
VL - 16
SP - 47
EP - 59
JO - Current Drug Targets
JF - Current Drug Targets
SN - 1389-4501
IS - 1
ER -